|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2003-12-17
|
|
pubmed:abstractText |
The aim of this work was to evaluate the long-term immunological and clinical impact of idiotype (Id) vaccination in multiple myeloma (MM) patients in first remission after high-dose chemotherapy. A total of 15 patients received a series of subcutaneous (s.c.) injections of autologous Id, conjugated to keyhole limpet hemocyanin (KLH) and in association with low doses of GM-CSF. The median duration of follow-up was 110 months from diagnosis. The vaccine induced immune responses that lasted almost 2 years after the end of treatment. Antibody responses included anti-KLH IgM and IgG (90% of patients), anti-KLH IgE (30%), anti-GM-CSF IgG (20%), anti-Id IgG (20%), and anti-Id IgE (30%). Id-specific delayed type hypersensitivity skin tests were positive in 85% of tested patients. Following vaccination, a progressive recovery of T-cell receptor (TCR) diversity was observed and the loss of oligoclonality was significantly correlated with the remission duration. Although Id/KLH conjugates did not eliminate the residual tumor burden, the median progression-free survival, and overall survival were 40 and 82 months, respectively. A retrospective case-matched analysis showed similar results in patients treated with IFN-alpha alone or in association with steroids. This vaccine formulation can overcome Id-specific immune tolerance by inducing clinical responses that are worthy of further investigation.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Anti-Idiotypic,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Glucocorticoids,
http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte-Macrophage...,
http://linkedlifedata.com/resource/pubmed/chemical/Hemocyanin,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin Idiotypes,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Antigen, T-Cell,
http://linkedlifedata.com/resource/pubmed/chemical/keyhole-limpet hemocyanin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0887-6924
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
139-45
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:14574332-Adjuvants, Immunologic,
pubmed-meshheading:14574332-Antibodies, Anti-Idiotypic,
pubmed-meshheading:14574332-Antibodies, Neoplasm,
pubmed-meshheading:14574332-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:14574332-Case-Control Studies,
pubmed-meshheading:14574332-Combined Modality Therapy,
pubmed-meshheading:14574332-Follow-Up Studies,
pubmed-meshheading:14574332-Glucocorticoids,
pubmed-meshheading:14574332-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:14574332-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:14574332-Hemocyanin,
pubmed-meshheading:14574332-Humans,
pubmed-meshheading:14574332-Hypersensitivity, Delayed,
pubmed-meshheading:14574332-Immunity, Cellular,
pubmed-meshheading:14574332-Immunoglobulin Idiotypes,
pubmed-meshheading:14574332-Injections, Subcutaneous,
pubmed-meshheading:14574332-Interferon-alpha,
pubmed-meshheading:14574332-Middle Aged,
pubmed-meshheading:14574332-Multiple Myeloma,
pubmed-meshheading:14574332-Neoplasm Staging,
pubmed-meshheading:14574332-Receptors, Antigen, T-Cell,
pubmed-meshheading:14574332-Remission Induction,
pubmed-meshheading:14574332-Retrospective Studies,
pubmed-meshheading:14574332-Survival Rate,
pubmed-meshheading:14574332-Treatment Outcome,
pubmed-meshheading:14574332-Vaccination
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy.
|
|
pubmed:affiliation |
Centro di Ricerca in Medicina Sperimentale, Ospedale San Giovanni Battista, Torino, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
